Breast Cancer: Current Research
91吃瓜
Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ 91吃瓜 Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
91吃瓜 Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Citations : 114
Indexed In
- RefSeek
- Hamdard University
- EBSCO A-Z
- Publons
- ICMJE
Useful Links
Recommended Journals
Related Subjects
Share This Page
Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in breast cancer: A meta-analysis
4th World Congress on Breast Cancer
Guochao Zhang, Xue Qi, Likun Huang
Chinese Academy of Medical Sciences and Peking Union Medical College, China Shanxi Provincial People芒�?�?s hospital, China
Posters & Accepted Abstracts: Breast Can Curr Res
DOI:
Abstract
Background: Programmed death ligand-1 (PD-L1) is an immunological checkpoint protein that has recently been found to be associated with the prognosis of various malignancies. However, the association between PD-L1 expression and the survival of breast cancer patients has remained unclear. Therefore, the aim of the present meta-analysis was to assess the clinical value of PD-L1 in breast cancer patients. Methods: MEDLINE/PubMed, EMBASE, Cochrane Library, and Grey Literature databases were searched up to 30 March 2016 for articles involving an association between PD-L1 expression and breast cancer prognosis. Hazard ratios for overall survival with 95% confidence intervals (CIs) according to the expression status of PD-L1 were calculated. Odds ratios (ORs) were also analyzed to evaluate the association between clinicopathological parameters and PD-L1 expression. Results: Ten studies were included in this meta-analysis and 7 of these described clinicopathological features. Elevated levels of PDL1 were only significantly associated with histological grade (OR = 1.86, 95% CI: 1.38芒�?�?2.51; Pheterogeneity = 0.0196), estrogen receptor status (ER) (OR = 0.36, 95% CI: 0.17芒�?�?0.75; Pheterogeneity = 0.000), and progesterone receptor status (PR) (OR = 0.31, 95% CI: 0.11芒�?�?0.86; Pheterogeneity = 0.000). Conclusion: There were trends observed in the present meta-analysis, although PD-L1 status as a predictor of prognosis for patients with breast cancer could not be confirmed. Therefore, further studies of mechanism(s) related to PD-L1 expression level and immune escape and antitumor immune responses are needed, especially in relation to breast cancer subtypes. Furthermore, an evaluation standard for PD-L1 expression would facilitate all future studies.Biography
Zhang Guochao is working as a resident for the second year in Peking Union Medical College and Hospital at present.
Email: 1210548954@
